Litigators of the (Past) Week: A Defense Win for Gilead and Teva in a Rare Trial on Pay-For-Delay Claims
With Bart Williams of Proskauer and Devora Allon of Kirkland representing Gilead and Christopher Holding of Goodwin Procter representing Teva, the pharmaceutical companies beat back $3.6 billion in antitrust claims at trial in San Francisco stemming from an alleged "pay-for-delay" scheme involving two HIV drugs.
July 12, 2023 at 07:30 AM
21 minute read
PharmaceuticalsTrials in "pay for delay" antitrust cases—where branded and generic pharmaceutical companies stand accused of settling patent litigation claims in a way that unfairly props up drug prices—rarely go to trial. Given the dollar figures involved and the prospect of treble damages, the risks are high. That was especially true in a case that wrapped up recently against Gilead Sciences Inc. and Teva Pharmaceutical Industries Ltd. alleging the companies colluded to unfairly inflate the price for two key HIV drugs.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
NOT FOR REPRINT
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
Law Firms Mentioned
Trending Stories
- 1The Law Firm Disrupted: For Big Law Names, Shorter is Sweeter
- 2Wine, Dine and Grind (Through the Weekend): Summer Associates Thirst For Experience in 'Real Matters'
- 3'That's Disappointing': Only 11% of MDL Appointments Went to Attorneys of Color in 2023
- 4What We Know About the Kentucky Judge Killed in His Chambers
- 5'I'm Staying Everything': Texas Bankruptcy Judge Halts Talc Trials Against J&J
Featured Firms
Law Offices of Gary Martin Hays & Associates, P.C.
(470) 294-1674
Law Offices of Mark E. Salomone
(857) 444-6468
Smith & Hassler
(713) 739-1250